[
Abstract]
[
Full Text HTML]
[
Full Text PDF] （in Japanese / 360KB）
[Members Only] J.Jpn. Surg. Soc.. 118(4): 395-401, 2017
Feature topic
ROLE OF CONVERSION SURGERY FOR UNRESECTABLE OR RECURRENT COLORECTAL CANCER
A major challenge in the management of unresectable or recurrent colorectal cancer is the multidisciplinary approach including surgery. Resection is the most important treatment strategy for long-term survival. Even when resection is not possible as primary treatment, curative treatment is sometimes possible after effective chemotherapy. Therefore, resection should always be kept in mind when conducting chemotherapy for unresectable or recurrent colorectal cancer. Anti-epidermal growth factor receptor (EGFR) antibody has resulted in high response rates in RAS wild-type colorectal cancer patients in the neoadjuvant setting. However, it has not been elucidated whether anti-EGFR antibody is superior to anti-vascular endothelial growth factor antibody as neoadjuvant chemotherapy for unresectable colorectal cancer. Several randomized studies on first-line therapy for advanced colorectal cancer are now being conducted. Adequate regimens for neoadjuvant chemotherapy and the real conversion surgery rate in Japan will be elucidated in the near future.
To read the PDF file you will need Adobe Reader installed on your computer.